Travere Therapeutics secured full FDA approval of FILSPARI in September 2024, positioning itself at the forefront of non-immunosuppressive therapies for primary IgA nephropathy (IgAN). The firm has since invested in building a specialized U.S. sales force to drive market penetration, while leveraging international licensing arrangements. Despite progress, challenges remain from regulatory uncertainties, generic competition on legacy products, and complexities in physician and payer adoption. Financial trends through FY2025 indicate substantial improvement in operating losses and cash flow but continued net losses persist amid measured capital expenditures.